Login to Your Account



InterMune's Missed Endpoint, Survival Benefit Raise Stock

By Karen Young


Thursday, August 29, 2002
InterMune Inc. reported top-line results from a Phase III trial of Actimmune in the treatment of idiopathic pulmonary fibrosis that, while failing to meet its primary endpoint of progression-free survival, showed a survival benefit. (Bioworld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription